Company intelligence / Profile preview

CuraLife

Los Angeles, California, United Statescuralife.com ↗

Ownership: Private
Employees: ~32
Development stage: Commercial

Overview

CuraLife’s lead product, CuraLin, is a clinically validated herbal supplement shown in randomized controlled trials to significantly reduce HbA1c as an add-on therapy for adults with type 2 diabetes. The company’s new product Curaslim targets weight loss by naturally boosting GLP‑1 production and has demonstrated clinically validated results for sustainable weight management. Both products are supported by digital health tools and personalized care models[1][3][4][5].

Therapeutic areas: Endocrinology
Modalities: Herbal supplementNutraceuticalsDigital therapeutics (platform)
Industry: Food & Nutrition

Drug pipeline

2 assets

Curalin

Commercial

Indications: Type 2 diabetes

1 more asset in the full pipeline.

Partnerships

LYC Healthcare – exclusive distribution agreement for Malaysia and Singapore

Beyond the preview

Go deeper on CuraLife.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CuraLife.